How to buy Aclaris Therapeutics stock | $22.24

Aclaris Therapeutics, Inc is a biotechnology business based in the US. Aclaris Therapeutics shares (ACRS) are listed on the NASDAQ and all prices are listed in US Dollars. Aclaris Therapeutics employs 57 staff and has a trailing 12-month revenue of around 0.00.

Aclaris Therapeutics stock price (NASDAQ: ACRS)

Use our graph to track the performance of ACRS stocks over time.

Aclaris Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$22.24
52-week range	$1.82 - $30.38
50-day moving average	$17.00
200-day moving average	$21.03
Wall St. target price	$34.20
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-4.17

Buy Aclaris Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Aclaris Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Aclaris Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aclaris Therapeutics price performance over time

Historical closes compared with the close of $22.24 from 2021-05-28

1 week (2021-07-23)	N/A
1 month (2021-07-02)	30.29%
3 months (2021-05-03)	-10.75%
6 months (2021-01-30)	N/A

1 year (2020-07-30)	N/A
2 years (2019-07-30)	N/A
3 years (2018-07-30)	N/A
5 years (2016-07-30)	N/A

Aclaris Therapeutics financials

Revenue TTM	$6.9 million
Gross profit TTM	$-27,989,000
Return on assets TTM	-22.69%
Return on equity TTM	-75.77%
Profit margin	0%
Book value	$2.16
Market capitalisation	$907.4 million

TTM: trailing 12 months

Shorting Aclaris Therapeutics shares

There are currently 3.5 million Aclaris Therapeutics shares held short by investors – that's known as Aclaris Therapeutics's "short interest". This figure is 13.2% down from 4.0 million last month.

There are a few different ways that this level of interest in shorting Aclaris Therapeutics shares can be evaluated.

Aclaris Therapeutics's "short interest ratio" (SIR)

Aclaris Therapeutics's "short interest ratio" (SIR) is the quantity of Aclaris Therapeutics shares currently shorted divided by the average quantity of Aclaris Therapeutics shares traded daily (recently around 958423.49726776). Aclaris Therapeutics's SIR currently stands at 3.66. In other words for every 100,000 Aclaris Therapeutics shares traded daily on the market, roughly 3660 shares are currently held short.

However Aclaris Therapeutics's short interest can also be evaluated against the total number of Aclaris Therapeutics shares, or, against the total number of tradable Aclaris Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aclaris Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Aclaris Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.1138% of the tradable shares (for every 100,000 tradable Aclaris Therapeutics shares, roughly 114 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aclaris Therapeutics.

Find out more about how you can short Aclaris Therapeutics stock.

Aclaris Therapeutics share dividends

We're not expecting Aclaris Therapeutics to pay a dividend over the next 12 months.

Aclaris Therapeutics share price volatility

Over the last 12 months, Aclaris Therapeutics's shares have ranged in value from as little as $1.82 up to $30.375. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aclaris Therapeutics's is 0.6213. This would suggest that Aclaris Therapeutics's shares are less volatile than average (for this exchange).

Aclaris Therapeutics overview

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. .

Frequently asked questions

What percentage of Aclaris Therapeutics is owned by insiders or institutions?
Currently 7.267% of Aclaris Therapeutics shares are held by insiders and 79.924% by institutions. How many people work for Aclaris Therapeutics?
Latest data suggests 57 work at Aclaris Therapeutics. When does the fiscal year end for Aclaris Therapeutics?
Aclaris Therapeutics's fiscal year ends in December. Where is Aclaris Therapeutics based?
Aclaris Therapeutics's address is: 640 Lee Road, Wayne, PA, United States, 19087 What is Aclaris Therapeutics's ISIN number?
Aclaris Therapeutics's international securities identification number is: US00461U1051 What is Aclaris Therapeutics's CUSIP number?
Aclaris Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00461U105